Astragaloside IV inhibits gut FXR expression by reducing the abundance of BSH-expressing bacteria and decreasing BSH activity, thus increasing the level of T-β-MCA, which is often accompanied by a decrease in FGF15 and subsequent activation of hepatic FXR, leading to the inhibition of hepatic steatosis (Zhai et al., 2022). The gene discussed is NR1H4; the disease is fatty liver disease.